Quest's profits make it Barron's favourite:
This article was originally published in Clinica
Executive Summary
Quest Diagnostics is predicting that the doubling of its first-quarter profits, to $36 million, will lead to a full year earnings growth of at least 50%. Its position was noted by US financial weekly Barron's, which awarded Quest first place in its annual survey of the top 500 companies in the US. Quest says that it has been able to reduce costs from its 1999 acquisition of SmithKline Beecham Laboratories and is deriving higher margins from gene-based testing.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.